Because ectopic ACTH-secreting (EAS) tumors are often occult, improved imaging is needed. 
T
en percent of Cushing's syndrome is caused by ectopic ACTH-secreting (EAS) tumors (1-4). Although first described in patients with overt and metastatic tumors, more recent series include slow growing, usually intrathoracic, occult tumors (5, 6) . Identification and surgical removal of the tumor remains the optimal treatment for the management of EAS (7) . Thus, localizing these tumors is crucial.
Despite the use of anatomical imaging techniques like computed tomography (CT) and magnetic resonance imaging (MRI), up to 50% of EAS tumors cannot be found (8) .
[ 111 In-DTPA-D-Phe]Pentetreotide scintigraphy [octreotide (OCT)], a functional imaging modality, has shown promise in localizing these tumors (9 -16) . The ability of OCT to identify the tumors depends on multiple factors, including the dose of the radiopharmaceutical, the type and degree of somatostatin receptor expression, and tumor size (9 -11) . [ 
Patients and Methods
Between 1999 and 2009, after providing informed consent, 63 patients referred for presumed ectopic ACTH-secreting tumors were studied prospectively at the National Institutes of Health (NIH) Clinical Center under a protocol (Clinical Trials NCT00001849) approved by the Institutional Review Board and NIH Radiation Safety Committee. Six eucortisolemic patients were excluded. The remaining 57 patients underwent evaluation for the cause of ACTH-dependent Cushing's syndrome, which included CRH and dexamethasone suppression tests, pituitary MRI, and inferior petrosal sinus sampling (IPSS) (1) .
Sixteen patients whose IPSS results suggested Cushing's disease did not undergo further imaging studies. Each had an ACTH-positive tumor resected at transsphenoidal surgery. The remaining 41 patients underwent clinical and research imaging. CT, MRI, and LOCT imaging studies were reviewed by staff radiologists for routine clinical care; decisions regarding surgery were based on these findings and those of research radiologists in cases 5, 17, and 29, augmented by review of the investigational HOCT and PET scans. Surgery was recommended when at least one nonresearch study was clearly abnormal.
After an interim analysis showed that FDG-PET was not helpful (13) , DOPA-PET was substituted. Three-Tesla (T) chest MRI imaging, gated cardiac studies, and single-photon emission CT (SPECT)/CT for octreoscans were added when they became available.
Imaging
Patients underwent CT and MRI of neck, chest, abdomen, pelvis and LOCT every 6 -12 months until a tumor was identified. At intervals of no less than 12 months, HOCT was obtained if LOCT was inconclusive, and up to two PET scans were obtained.
Over the years, CT was performed with 8-, 16-, and 64-detector systems. Contrast agents were administered orally and iv. From 1999 -2009, CT section thickness from the neck to the adrenal glands decreased from 5 to 1 mm; otherwise, section thickness was 10 mm. When it became available, 64-slice gated cardiac CT was performed with and without iv contrast.
T1 spin echo and T2 MRI images were obtained with and without gadolinium using a 1.5-T scanner. The 3-T chest MRI (using scan thickness of 5-8 mm depending on the patient's size) and cardiac MRI (using a six-element cardiac phased-array receiver coil, and vector electrocardiographic gating) were performed when available if the patients could tolerate the examination.
Generally, LOCT images were obtained 4 and 24 h and HOCT images 4, 24, and 48 h after injection; rarely, further delayed images were obtained. Planar whole-body images were obtained at 4 h, and SPECT was obtained at all time points. SPECT/CT was used when it became available in 2008.
PET images were obtained after 6 h fasting with a GE Advance PET scanner and iterative reconstruction. Forty minutes after FDG (20 mCi) injection, images were acquired from upper thighs to forehead. Initially, 10-min two-dimensional emission and 8-min transmission scans were acquired. Later, the transmission time was changed to 3 min. PET was performed without CT coregistration. For DOPA-PET, five patients were pretreated with 200 mg carbidopa. Images were acquired from upper thighs to mid-forehead 30 min after injection (12 mCi F-DOPA) and from mid-abdomen to the thorax 105 min after injection. The emission time was 5 min with 3-min transmission scans.
Data collection and statistical analysis
Clinical nuclear medicine and radiology staff were not blinded to other available imaging results; they provided prospective readings. MRI and CT were prospectively and retrospectively reviewed by research staff, who considered all imaging results. LOCT, HOCT, and PET scans were read prospectively in a blinded fashion. All prospective data were considered for patient care purposes.
All retrospective reviews were done without knowledge of the pathology findings, except for patient 26. In Table 1 , we note whether the retrospectively reviewed results were positive and the original clinical report negative [cases 5 (CT), 13 (F-DOPA), 14 (MRI and LOCT), 26 (CT), and 27 (LOCT)].
Patients were divided into tumor-found and occult disease groups. In tumor-found patients, imaging findings for individual lesions were classified as true or false positive according to the actual tumor location. In occult patients, all imaging findings were classified as questionable lesions because they were not confirmed pathologically. Findings with nontumor explanations (e.g. fractures, calcified pulmonary nodules, liver cysts, hemangiomas, adrenal hyperplasia, and vascular ectasia or anomalies) were excluded from analysis.
The largest tumor diameter measured at pathology was recorded, except for case 7, where the MRI measurement was used. Tumor size was not available for patients with metastatic disease and/or multiple enlarged lymph nodes. Data are presented as mean Ϯ SD. Logarithmic transformation was applied for nonnormally distributed data before analysis. An unpaired t test compared mean tumor sizes. P values Ͻ 0.05 were considered significant. The sensitivity and positive predictive value (PPV) with 95% confidential intervals (CI) for each imaging modality or combination was calculated for individual patients (not lesions) (17) . In the tumor-found group, we analyzed only the studies performed during the last, presurgical, evaluation. In the occult disease group, studies performed at the most recent follow-up visit are shown. The duration of follow-up was calculated from the dates between the initial and the most recent visits, except in one patient who was evaluated initially with CT and MRI in 1990 under another protocol.
Results
Thirty patients (17 female) aged 45 Ϯ 13.6 (23-69) yr had EAS based on biopsy or removal of a neuroendocrine tumor (Table 1) . Twenty-five tumors stained positively for ACTH. The others stained positively for neuroendocrine tumor markers; ACTH immunohistochemistry was negative in three patients or not done in two patients. Four of these five patients had normal or low ACTH and cortisol values after tumor removal; one patient with negative ACTH immunochemistry had inoperable disease.
Eleven patients (three female) aged 54.1 Ϯ 14.4 (33-82) yr had presumed occult EAS, based on negative IPSS and imaging results (18) ( Table 2 ). Sixteen patients, including three patients with occult EAS, were reported previously (13).
Tumor-found group

Patients with initial positive imaging
Seventeen of 18 patients (Table 1, Between 1 and 5 months before evaluation at NIH, eight patients had imaging of the actual tumor location. CT scan in two of eight patients (no. 14 and 15) did not report any lesion. In five others (no. 1, 4, 11, 12, and 16), lesions on CT were identified as nonspecific nodules or abnormalities rather than possible tumor. One patient (no. 7) had a pituitary MRI that did not report an adjacent neuroethesioblastoma.
At the NIH, CT identified at least one site of disease in all 18 patients. All except case 14 received contrast. Thoracic slice thickness of 5 mm (cases 3, 6, 8, and 12) detected tumors with a mean diameter of 3.3 Ϯ 3.2 cm (median 1.9, range 1.3-8); slice thickness of 1.2 mm (cases 2, 9, 10, and 13-18) identified tumors with a significantly lower mean tumor diameter of 1.2 Ϯ 0.4 (median 1.0, range 0.8 -2) cm (P ϭ 0.03).
MRI localized tumors in 16 of 17 patients; the size was 2.3 Ϯ 2.1 (median 1.6, range 0.8 -8) cm. All were bright on T2-weighted images. Only seven patients, including the one with the false-negative scan, received gadolinium. When patients with intrathoracic lesions had 1.5-T and cardiac or 3-T MRI of the chest (n ϭ 2 and 6), both studies identified the same abnormalities.
A
LOCT localized tumor in 11 of 18 patients, including one case (no.14) that was read retrospectively as borderline positive after HOCT was clearly abnormal. The mean diameter of tumors identified by LOCT was 3.0 Ϯ 2.4 (median 1.9, range 0.8 -8) cm. HOCT identified tumor in four of eight patients with negative or equivocal LOCT. The diameter (1.1 Ϯ 0.6; median 0.9, range 0.8 -2 cm) was not significantly different from that detected by LOCT (P ϭ 0.43). All 14 patients identified by LOCT/HOCT had corresponding lesions on CT, and 12 of 14 had corresponding lesions identified on MRI (Table 1) .
All 18 patients in this group underwent either FDG-or F-DOPA-PET scans; tumors were identified in seven of 10 FDG-PET and five of eight F-DOPA scans. Lesions detected by FDG-PET had a mean diameter of 2.6 Ϯ 1.9 (median 1.8, range 0.8 -5.8) cm, and those detected by F-DOPA had a mean diameter of 2.6 Ϯ 3.4 (median 1.6, range 0.9 -8) cm. MRI and/or CT imaging also identified these lesions.
Tumor-found group with positive imaging on follow-up visit
After initially inconclusive imaging at NIH, 12 patients (Table 1 , patients 19 -30) had positive follow-up imaging and successful surgery a median of 28 (range 9 -99) months after initial imaging. Two patients had mediastinal recurrence of pulmonary carcinoid. The mean tumor diameter in the other 10 was 1.3 Ϯ 0.9 (median 0.8, range 0.65-3) cm. Although this was smaller than that of the tumors found on initial workup, the difference was not statistically significant (P ϭ 0.08).
Conventional CT identified thoracic tumors in 10 of 11, using 1.2-mm (seven of eight tumors detected, diameter 0.65-3 cm) or 5 mm (three of three tumors detected, all 0.8 cm diameter) sections (Fig. 1) . Patient 30 did not receive contrast. Cardiac CT in two patients confirmed the lesions seen on conventional scans. In case 26, mediastinal exploration for evaluation of lymphadenopathy seen on CT unexpectedly revealed a tumor at the inferior pulmonary ligament, whereas the lymph nodes seen on CT proved pathologically negative. In retrospect, the tumor was present on the CT scan. When follow-up scans used thinner thoracic sections compared with earlier studies (cases 19, 22, 24, and 28), retrospective unblinded review of the images identified all tumors on the earlier images regardless of slice thickness. One of these had been reported as suspicious, whereas the other lesions had originally been described as nonspecific findings.
MRI identified tumor in 10 of 12 patients. Seven received gadolinium, including one with negative results. Intrathoracic tumor was detected in five of six who had 1.5-and 3-T MRI and in three who also had cardiac MRI. One patient had tumor identified by 3-T but not 1.5-T MRI.
Staff radiologists did not report culprit lesions on CT/ MRI in three patients (no.19, 26, and 29). The research radiologist identified lesions on CT retrospectively in patient 26 and prospectively by MRI and CT in patients 19 and 29.
LOCT localized tumor in five of 10 patients, including one seen retrospectively after a positive high-dose scan in patient 27. HOCT was negative in two patients and positive in patients 27 and 29 (in whom HOCT was performed to evaluate lymph nodes).
DOPA-PET accurately localized tumor in one of three patients on follow-up before surgery. FDG-PET was performed in one patient and was negative.
False-positive studies
In the patients with surgically resected lesions, falsepositive CT findings (Table 1 , parentheses) were found in 15 of 30 patients (50%). In the thorax, these lesions were found at a similar frequency with 1-to 1.2-mm (eight of 17) and 5-mm (five of 11) sections. False-positive lesions included thyroid, pulmonary, or pleural nodules; enlarged lymph nodes; and pelvic and liver lesions. Lymph nodes were considered to be false positive if they were pathologically negative or not found in the region of the primary tumor.
With MRI, false positives were more common with 1.5-T (6 of 27 patients) than with the 3-T magnet (one of 13 patients); these were the same types of lesions seen on CT.
False-positive pulmonary results were found in four of 28 patients with LOCT and one of 12 with HOCT. Two of eleven patients undergoing FDG-PET had multiple foci of false-positive uptake in the mediastinum, lungs, hilum, and liver. No false-positive findings were noted with F-DOPA-PET.
Occult EAS patients (Table 2)
Eleven patients with EAS remained occult at last evaluation (Table 2 ). Of these, three (cases 38 -40) had only one evaluation at NIH; two patients died within 6 months after discharge, and one was unwilling to return. One patient who died before readmission for HOCT had a 0.8-cm lung lesion on CT and MRI but not LOCT. The others had discordant or negative findings.
The remaining patients (cases 31-37 and 41) were followed for 9 -198 months. Three (cases 32, 34, and 35) had failed surgery/negative biopsies during this follow-up period for concordant false-positive findings on CT and MRI (Table 2) . Another patient (36) had failed exploratory surgery and subsequent inconclusive imaging for 16 yr. At their last visit, all eight patients had CT, MRI, and LOCT, and six of eight had HOCT. Six of eight had either FDG-PET or F-DOPA-PET imaging.
At last evaluation, CT and MRI identified subcentimetric concordant lesions in four of eight patients (31, 33, 34, and 41); OCT was negative. Patient 31 has an 8-mm retrocardiac mass but due to cyclic hypercortisolism and low ACTH levels has not undergone surgery. Case 33 has two small lesions on CT; one with poorly defined borders was also seen on MRI. Case 41 has atypical 8-mm elongated inhomogeneous lesion. In patient 34, a 7-mm lung nodule resected incidental to cardiac surgery was a scar.
Sensitivity, PPV, and false positives for individual and combined imaging modalities (Tables 3-5)
For the tumor-found group, DOPA-PET and HOCT had the lowest sensitivity on a per-patient basis, and the other modalities had overlapping CI: CT 93% (95% CI ϭ 79 -98%), MRI 90% (95% CI ϭ 74 -96%), LOCT 57% (95% CI ϭ 39 -73%), HOCT 50% (95% CI ϭ 25-75%), FDG 64% (95% CI ϭ 35-85%), and F-DOPA 55% (95% CI ϭ 28 -79%). By modality, the fraction of patients with at least one false-positive finding was 50% by CT, 31% by MRI, 18% by L/HOCT, and 18% by FDG-PET.
On a per-lesion basis, PPV were 100% for DOPA-PET, 89% for HOCT, 79% for LOCT, 74% for MRI, 66% for CT, and 53% for FDG-PET. For FDG-PET, seven (47%) of 15 lesions proved false positive, whereas with F-DOPA-PET, there were no false-positive findings. When considering all patients (tumor-found and occult), per-patient sensitivities decreased and the percent of false-positive findings increased, as expected.
Combining functional with anatomic imaging by requiring abnormal CT or MRI and an abnormal L/HOCT increased PPV for individual lesions to 93% (CT) and 100% (MRI) (Tables 4 and 5) . The combination of CT and MRI alone had a lower lesion PPV (80%) but higher sensitivity (83%) for individual patients. F-DOPA-PET similarly improved PPV of CT/MRI; FDG-PET did not.
Discussion
Imaging studies are the cornerstone of the management of EAS, because early localization and surgical removal of tumor constitutes optimal treatment. This study explored five questions related to localization of these tumors. 1) Which imaging modality or combination best detects tumors? 2) Is there any strategy to reduce the problem of false-positive results? 3) Does the technique used for any given modality influence the results? 4) What might explain negative results? 5) How does the method of interpretation affect the results?
Most tumors causing EAS are intrathoracic (83% in this series) (3, 4, 7, 19) . This suggests that initial imaging should focus on the chest. Of tumors identified at the first visit in this study, 14 of 18 were intrathoracic, whereas four were in the brain, abdomen, or neck. By contrast, in 12 patients whose tumor was identified on follow-up visits, 11 had intrathoracic tumors and one had pancreatic neuroendocrine tumor. These data support a strategy of performing thoracic studies first at all visits, with the understanding that additional scans may be required.
The conclusion of this study agrees with de Herder and Lambert's editorial analysis (20) that no single imaging technique has optimal accuracy. The choice of imaging modalities is guided by the sensitivity of the procedure balanced by the risk of false-positive findings. One way to address the problem of false-positive results is to obtain two different types of imaging on the premise that falsepositive lesions would not be concordant in both. In patients with identified tumors, the combination of two anatomic modalities, CT and MRI, had a per-patient sensitivity of 83% and a PPV per lesion of 80%. Perhaps more useful was the combination of anatomic and functional imaging. For instance, MRI and LOCT/HOCT resulted in a sensitivity of 63% and PPV of 100%. One patient with falsely negative LOCT/HOCT and pulmonary carcinoid had a positive F-DOPA PET, suggesting that the latter may also be a helpful adjunct. As expected, the combination of two positive imaging modalities decreases sensitivity but increases specificity, particularly with functional imaging. Functional imaging reduces false-positive results because it relies on the specific properties of tumor cells, not just their anatomic characteristics. However, tumors lacking the relevant receptors (OCT), metabolic rate (FDG-PET), or amine precursor uptake (F-DOPA) have falsenegative results (9) . F-DOPA-PET had lower sensitivity (50%) in our study than in reports comprising mainly hindgut carcinoids (88 -93%) (21, 22) . In EAS, FDG-PET is most likely to detect metabolically active tumors or adrenal pheochromocytomas (23) . Because occult tumors may be metabolically less active, it is not surprising that FDG-PET best localizes overt and not occult disease (13) . Tsagarakis et al. (24) demonstrated a high diagnostic yield of LOCT in localizing EAS tumors; the modality identified tumor in all six patients with bronchial carcinoids, either initially or during follow-up evaluation. In contrast, Koopmans et al. (25) reported lower LOCT sensitivity compared with DOPA-PET (46 vs. 96%) in patients with metastatic gastrointestinal carcinoids. Our study suggests that use of a higher dose should be considered for OCT, because three of nine patients with negative LOCT scans were positive with HOCT, two others were retrospectively read as positive after identification by HOCT, and another was confirmed positive on HOCT. When new radioligands with increased affinity to all somatostatin subtype receptors become available, the sensitivity of OCT also should increase.
With improved imaging techniques over time, anatomical studies including CT (thinner 1.2-mm sections, chest) and MRI (3-T magnet) may better detect smaller tumors. This study did not address this question directly, because patients did not receive CT scans of different slice thickness at the same visit, and few had both 1.5-and 3-T MRI. Also, use of CT coregistration with PET may enhance its utility.
Cardiac imaging suppresses myocardial motion and may thus enhance detection of small tumors adjacent to the heart TABLE 4. Sensitivity for the combinations of the anatomical and functional imaging modalities in subjects whose tumor was identified and in all subjects with EAS The PPV is identical for both groups of patients. TP, True positive.
and/or great vessels. It can also demonstrate the extent of tumor involvement of cardiac structures to help direct surgery. However, because it is relatively new, few patients in our study underwent this imaging modality; the role of cardiac gating in tumor localization should be explored further. Finally, PPV for each modality will differ among interpreting radiologists. In this study, routine clinical interpretations by staff radiologists did not identify all tumors. Compared with the clinical interpretations, the prospective research interpretation identified tumors smaller than 1 cm on CT and/or MRI in four patients, and the retrospective interpretation identified lesions in three others. Retrospective unblinded review of previous CT images with thicker thoracic sections identified tumors that had been identified prospectively on the clinical and/or research readings but were not reported as culprit lesions in four patients. Similarly, eight patients whose tumors were detected on initial evaluation at the NIH had recent outside imaging that did not identify the tumor(s). We were not able to clarify whether this represented differences in Unshaded (white background) boxes indicate that the test was done; those that are unfilled were positive, while those that were negative are indicated as such. Gray boxes indicate that the test was not done. Negative Octreotide scan doses are indicated as L (low dose, 6 mCi) or H (high dose, 18 mCi). When only L is indicated, the higher dose scan was not done. NEG, Negative; PT ID, patient identification number.
technique or interpretation or whether the 1-to 5-month gap between the studies might be important. Based on this experience, if tumors are not identified at initial evaluation, we recommend that the patient be referred to a highly specialized center to obtain additional imaging and interpretation by an experienced team of radiologists.
Tumors were best detected by correlating different imaging modalities. Knowledge of the facts that these tumors are often quite small and occur in locations that are unusual (e.g. epicardiac fat) or difficult to visualize or interpret (retrocardiac or pancreatic) may assist in their identification.
These results are potentially biased by our definition of false-positive lesions. Only suspicious lesions consistent with tumor, which could not be otherwise explained, were defined as positive. Inclusion of all lesions noted on reports would lead to even more false-positive findings and lower PPV.
This study has other limitations. PET examinations were performed without CT, which enhances accuracy. Some imaging techniques (e.g. F-DOPA-PET and HOCT) are not widely available, thus decreasing the translation of these results to practice. Also, not all imaging was performed at each visit. In addition, the study is small, and other tumor types might not be found with the same frequency.
In conclusion, we suggest that initial imaging of patients with presumed EAS include thoracic CT and MRI followed by LOCT. Further investigations in a larger population with different tumor types and amounts of tumor burden are necessary to confirm and extend these findings and determine the best imaging studies and/or their combinations for the detection of ectopic ACTH-producing tumors.
